1.46 billion people, one of the world's fastest growing clinical trial markets, an 80% CAGR from 2019–2024, and the world's most diverse genetic tapestry; India's clinical research moment has arrived.
India is the world's most populous country, having overtaken China in 2023, with an estimated population of roughly 1.46 billion in 2025 and one of the world's largest and fastest growing major economies. It is home to the world's largest generic pharmaceutical industry; producing approximately 20% of global generic drug supply; and is rapidly emerging as a major destination for innovator drug clinical trials. India's clinical trial volume has grown at an 80% compound annual growth rate from 2019 to 2024, propelling it to become the world's third-largest trial destination as of 2024.
Clinical trials are regulated by the Central Drugs Standard Control Organization (CDSCO) under the Ministry of Health and Family Welfare, through the office of the Drugs Controller General of India (DCGI). The New Drugs and Clinical Trials Rules 2019 significantly modernized India's regulatory framework, streamlining approvals, introducing concurrent CDSCO and ethics committee review, and opening up earlier-phase research. All trials must be registered on the Clinical Trial Registry; India (CTRI), maintained by ICMR's National Institute of Medical Statistics.
India's 1.44 billion people are among the most genetically and ethnically diverse in the world; a direct consequence of millennia of population migrations, geographic isolation, and endogamy within thousands of distinct communities. The country contains more genetic diversity within its borders than exists between Europe and Sub-Saharan Africa. This makes India uniquely valuable for pharmacogenomics research, rare genetic disease studies, and trials seeking to demonstrate efficacy across diverse ancestry groups.
India's disease burden is characterized by a dual challenge: a high continuing burden of infectious diseases (tuberculosis, dengue, HIV) alongside a rapidly growing epidemic of non-communicable diseases (diabetes, cardiovascular disease, cancer). The country has the world's largest population of people with diabetes (~77 million) and is experiencing rapidly rising cancer incidence. Crucially, many of India's patients are treatment-naïve; particularly in oncology and rare diseases; providing large, uncontaminated patient pools for Phase II and III trials.
The 3 Ps: India's clinical research appeal is captured by Population, Patients, and Physicians. 1.4 billion diverse people; large treatment-naïve patient pools across oncology, metabolic, and infectious disease; and over 1.3 million doctors; many trained internationally; providing investigator depth that few countries can match at this scale and cost point.
India's core proposition is the combination of massive, diverse, treatment-naïve patient populations with significantly lower operational costs than Western markets; and improving regulatory predictability under the 2019 rules. Bristol-Myers Squibb has invested over $100M in India for early-stage drug development through a Hyderabad GCC. Novartis runs 52 active trials in India across 335 sites. Phase II and Phase III trial registrations have grown 20% year-on-year since 2019, reflecting rising international confidence.
Concurrent CDSCO and ethics committee review under 2019 Rules; 12–16 week approval timeline; mandatory CTRI registration ensuring transparency; Sugam e-governance platform for digital submissions.
Operational costs 40–60% lower than the US; competitive investigator fees; lower site overhead; large volumes of patients per site reducing per-patient recruitment costs; ICH-GCP compliant data at significant savings.
1.44 billion people with unmatched genetic diversity; large treatment-naïve pools in oncology, TB, diabetes, and rare diseases; world's largest diabetic population; rapidly rising cancer incidence across head & neck, GI, and cervical types.
1.3M+ doctors; Tata Memorial Centre (700+ active trials; India's largest cancer network); AIIMS network; IITs contributing biomedical engineering; major pharma GCCs in Hyderabad, Bengaluru, and Mumbai.
Oncology dominates India's registered trials, accounting for approximately 41% of all cancer-related studies in the CTRI registry, with particular strength in head and neck cancers, cervical cancer, breast cancer, and GI cancers; all of which have exceptionally high Indian incidence. Infectious disease (including TB, HIV, and tropical diseases unique to the Indian subcontinent) is the second major area, reflecting India's position as a critical site for global health and neglected disease research. The Phase II and Phase III ratio is strengthening as India matures beyond early-stage generic equivalence work into innovator drug development.
Tata Memorial Centre in Mumbai is India's undisputed oncology trial leader, with over 700 active trials; among the highest volumes of any single site in Asia. AIIMS New Delhi is the national reference academic medical center. Hyderabad, Bengaluru, and Pune have emerged as major pharmaceutical and biotech research hubs, hosting growing numbers of Phase I units and CRO operations.
| # | Site | City | Notes |
|---|---|---|---|
| 01 | Tata Memorial Centre (TMC) | Mumbai | India's premier cancer research institution; 700+ active clinical trials; among Asia's highest single-site volumes; head & neck, breast, GI, hematology, and GYN oncology; government-funded; international collaborations with NCI, EORTC |
| 02 | All India Institute of Medical Sciences (AIIMS); New Delhi | New Delhi | India's most prestigious government medical institution; broad Phase I–IV portfolio across oncology, cardiology, neurology, and rare diseases; national reference for clinical standards; largest patient catchment in North India |
| 03 | Christian Medical College (CMC) Vellore | Vellore, Tamil Nadu | India's most internationally recognized academic hospital for quality research; infectious disease, hematology, and clinical pharmacology specialist; longstanding WHO and NIH partnerships; exceptional GCP compliance record |
| 04 | Postgraduate Institute of Medical Education and Research (PGIMER) | Chandigarh | North India's leading academic research institution; oncology, nephrology, and neurology trials; access to Punjab, Haryana, and Himachal Pradesh patient populations; strong Phase II–IV track record |
| 05 | Kasturba Medical College (KMC); Manipal | Manipal / Mangaluru | Manipal Academy of Higher Education network; broad multi-specialty trials; oncology, cardiology, and endocrinology; South Karnataka and Goa patient catchment; strong international sponsor relationships |
| 06 | Apollo Hospitals | Chennai / Hyderabad / National | India's largest private hospital network (70+ hospitals); JCI-accredited sites; oncology, cardiology, and orthopedics trials; NABH-accredited research centers; national geographic reach for multi-site enrollment |
| 07 | AIIMS Hyderabad / National AIIMS Network | Multiple cities | Government network of 22+ AIIMS institutions across India; standardized research infrastructure; oncology, rare diseases, and infectious disease trials; expanding access to North-East, Central, and Southern India patient populations |
| 08 | Kidwai Memorial Institute of Oncology | Bengaluru | Karnataka's dedicated cancer institute; Phase II–III oncology trials; broad tumor type coverage; access to Bengaluru's large and diverse patient population (12M+ metro); strong Phase III commercial portfolio |
| 09 | Dr. B. R. Ambedkar Medical College | Bengaluru | Bengaluru academic medical center; oncology, cardiology, and infectious disease trials; Karnataka population access; growing Phase II–IV commercial portfolio with CRO partnerships |
| 10 | Jawaharlal Nehru Medical College; AMU | Aligarh, Uttar Pradesh | Major North India academic hospital; access to Uttar Pradesh's 240M+ population; oncology, infectious disease, and metabolic trials; key site for reaching India's most populous state patient pool |
| 11 | Sri Ramachandra Medical College and Research Institute | Chennai | Private academic hospital; oncology, cardiovascular, and neurology trials; Tamil Nadu patient access; growing Phase I capability; international sponsor partnerships |
| 12 | Nizam's Institute of Medical Sciences (NIMS) | Hyderabad | Telangana government academic hospital; oncology, neurology, and nephrology trials; access to Telangana's diverse population; Hyderabad pharma hub proximity (Dr. Reddy's, Aurobindo, Bharat Biotech) |
| 13 | King Edward Memorial (KEM) Hospital | Mumbai | Municipal academic hospital; infectious disease, HIV, TB, and tropical medicine specialty; one of India's busiest hospitals by patient volume; critical site for neglected disease and global health trials |
| 14 | Amrita Institute of Medical Sciences | Kochi, Kerala | JCI-accredited private academic hospital; oncology, cardiology, and transplantation trials; access to Kerala's literate, health-aware patient population; strong international patient relationships |
| 15 | Cancer Institute (WIA) | Chennai | South India's oldest cancer institution (est. 1952); cervical cancer, breast, and GI oncology specialist; active Phase II–III commercial portfolio; access to Tamil Nadu's 80M population |
India's premier cancer research institution; 700+ active clinical trials; among Asia's highest single-site volumes; head & neck, breast, GI, hematology, and GYN oncology; government-funded; international collaborations with NCI, EORTC
India's most prestigious government medical institution; broad Phase I–IV portfolio across oncology, cardiology, neurology, and rare diseases; national reference for clinical standards; largest patient catchment in North India
India's most internationally recognized academic hospital for quality research; infectious disease, hematology, and clinical pharmacology specialist; longstanding WHO and NIH partnerships; exceptional GCP compliance record
North India's leading academic research institution; oncology, nephrology, and neurology trials; access to Punjab, Haryana, and Himachal Pradesh patient populations; strong Phase II–IV track record
Manipal Academy of Higher Education network; broad multi-specialty trials; oncology, cardiology, and endocrinology; South Karnataka and Goa patient catchment; strong international sponsor relationships
India's largest private hospital network (70+ hospitals); JCI-accredited sites; oncology, cardiology, and orthopedics trials; NABH-accredited research centers; national geographic reach for multi-site enrollment
Government network of 22+ AIIMS institutions across India; standardized research infrastructure; oncology, rare diseases, and infectious disease trials; expanding access to North-East, Central, and Southern India patient populations
Karnataka's dedicated cancer institute; Phase II–III oncology trials; broad tumor type coverage; access to Bengaluru's large and diverse patient population (12M+ metro); strong Phase III commercial portfolio
Bengaluru academic medical center; oncology, cardiology, and infectious disease trials; Karnataka population access; growing Phase II–IV commercial portfolio with CRO partnerships
Major North India academic hospital; access to Uttar Pradesh's 240M+ population; oncology, infectious disease, and metabolic trials; key site for reaching India's most populous state patient pool
Private academic hospital; oncology, cardiovascular, and neurology trials; Tamil Nadu patient access; growing Phase I capability; international sponsor partnerships
Telangana government academic hospital; oncology, neurology, and nephrology trials; access to Telangana's diverse population; Hyderabad pharma hub proximity (Dr. Reddy's, Aurobindo, Bharat Biotech)
Municipal academic hospital; infectious disease, HIV, TB, and tropical medicine specialty; one of India's busiest hospitals by patient volume; critical site for neglected disease and global health trials
JCI-accredited private academic hospital; oncology, cardiology, and transplantation trials; access to Kerala's literate, health-aware patient population; strong international patient relationships
South India's oldest cancer institution (est. 1952); cervical cancer, breast, and GI oncology specialist; active Phase II–III commercial portfolio; access to Tamil Nadu's 80M population
These are the primary regulatory, academic, and industry bodies shaping India's clinical research ecosystem.
National regulatory authority; 12–16 week CTA approval; New Drugs and Clinical Trials Rules 2019; Sugam e-governance portal; concurrent CDSCO and ethics committee review permitted; ICH-GCP aligned
Mandatory national registry (since 2009); 94,730+ trials registered since 2000; hosted by ICMR-NIMS; WHO ICTRP primary registry; public access to all trial information
India's apex body for biomedical research; funds investigator-initiated trials; manages CTRI; sets national ethical guidelines; Global Health Collaborative Research program
India's national cancer center; 700+ active trials; government-funded; head & neck, breast, GI, pediatric oncology; international collaborations with NCI, EORTC; National Cancer Grid anchor
India's most internationally regarded academic medical institution for research quality; infectious disease, hematology, and pharmacology excellence; WHO, NIH, and Wellcome Trust partnerships
National network of 22+ government research hospitals; standardized GCP infrastructure; oncology, rare diseases, cardiology, and neurology; expanding to underserved regions across India
Largest CRO operations in India; Mumbai, Hyderabad, Bengaluru, and Delhi offices; full Phase I–IV; regulatory affairs for CDSCO submissions; real-world evidence and data analytics
Bengaluru-based CRO (Biocon Group); integrated drug discovery through Phase II services; preclinical and clinical capabilities; global pharma partnerships
Global CRO with major India operations; Hyderabad and Mumbai offices; oncology, CNS, and rare disease specialty; CDSCO regulatory expertise
Major Indian pharma with growing global clinical trial operations; Hyderabad HQ; generic and innovator drug development; GCC supporting Bristol-Myers Squibb, Novartis, and others
India's 80% CAGR in clinical trials from 2019 to 2024 is not an anomaly; it reflects a structural shift driven by regulatory modernization, growing international confidence, and the country's irreplaceable patient assets. With roughly 1.46 billion people of extraordinary genetic diversity, large treatment-naïve patient pools, 40–60% cost savings versus Western markets, the world's largest diabetic population, and Tata Memorial Centre running 700+ active trials, India is no longer an emerging clinical market; it is a major one. For any sponsor building a globally diverse dataset, or seeking high-volume Phase III enrollment in oncology, metabolic, or infectious disease, India is increasingly essential.
Keep exploring
Discover 11 early-phase clinical trials and design frameworks redefining development strategy in 2025-2026, and what sponsors can learn to reduce late-stage failure risk.
Four pervasive AI misconceptions in clinical trials that derail programs, inflate costs, and create regulatory exposure, with evidence on what the data actually shows.
Before selecting an AI patient screening tool for clinical trial recruitment, ask these 7 critical questions to avoid costly mismatches and protocol failures.
Accelerated Approval is an FDA pathway that allows earlier approval of drugs treating serious conditions and filling unmet medical need on the basis of a surrogate endpoint that is reasonably likely to predict clinical benefit, conditional on confirmatory post-marketing trials.